HIV/AIDS: Strategies for an Endgame

• Bruce D. Walker, MD, Ragon Institute of MGH, MIT and Harvard
• Myron S. Cohen, MD, University of North Carolina at Chapel Hill
• Betsy Herold, MD, Albert Einstein College of Medicine
• Julie McElrath, MD, PhD, Fred Hutchinson Cancer Research Center (FHCRC)
• Gary Nabel, MD, PhD, Sanofi

Ending the HIV/AIDS Pandemic: Follow the Science

• Dr. Anthony S. Fauci, MD, NIAID, National Institutes of Health

Towards an HIV Vaccine: A Scientific Journey

• Dr. Anthony S. Fauci, MD, NIAID, National Institutes of Health

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

• Till Schoofs, MD, The Rockefeller University

Deciphering the molecular basis of unusually high neutralization resistance in a tier 3 HIV-1 strain

• Thandeka Moyo, PhD, University of Cape Town

Individualized Profiling of Germline Antibody V Genes

• Gunilla K. Hedestam, Karolinska Institutet

B Cell Clonal Dynamics During Sequential Immunizations

• Thomas B. Kepler, PhD, Boston University

F9, a new class of antibodies that neutralizes autologous tier 2 viruses in NHP immunized with liposome conjugated well-ordered trimers

• Paola Murillo, Karolinska Institutet

Antiretroviral treatment of acute HIV infection and the prospect for a functional cure

• Thumbi Ndung’u, BVM, PhD, University of KwaZulu-Natal

Broadly neutralizing antibodies development: Lessons from the Protocol C cohort

• Elise Landais, PhD, IAVI Neutralizing Antibody Center